突破性卒中后继续与转换直接口服抗凝药的比较
多中心注册队列模拟目标试验,纳入2020年2月至2025年2月欧洲和北非9国35个卒中中心连续成人房颤患者,均在持续直接口服抗凝药期间发生突破性缺血性卒中并恢复抗凝。463例(46.0%)继续原直接口服抗凝药,543例(54.0%)转换抗凝。经逆概率治疗加权后,转换组90天净临床获益4.9%,继续组5.1%,风险差-0.3个百分点(90%CI -2.7至2.1),达到预设非劣效标准;复发缺血事件和出血结局的绝对差异在预设非劣效界值内,但全因死亡和血管死亡未证明非劣效。作者认为转换无额外获益,需随机试验寻找改善二级预防的策略。
要点
- 房颤患者直接口服抗凝药治疗中发生突破性缺血性卒中后,转换抗凝90天净临床获益4.9%,继续原药5.1%,风险差-0.3个百分点(90%CI -2.7至2.1),达非劣效。
- 复发缺血事件和出血结局的绝对差异均在预设非劣效界值内。
- 全因死亡和血管死亡未证明非劣效。
- 作者认为转换抗凝相比继续同一直接口服抗凝药无额外获益。
适用人群与场景
- 成人房颤患者,在持续直接口服抗凝药治疗期间发生突破性缺血性卒中并随后恢复抗凝治疗;纳入2020年2月至2025年2月欧洲和北非9国35个卒中中心连续病例。
处置流程与药物剂量
- 转换组改为不同直接口服抗凝药或维生素K拮抗剂;对照组继续卒中前直接口服抗凝药。
研究设计与关键结果
- 多中心注册队列模拟目标试验,纳入1006例(中位年龄80.4岁,IQR 73.4-85.4;女性503例[50.0%],男性503例[50.0%]),463例(46.0%)继续原直接口服抗凝药,543例(54.0%)转换治疗。
- 经逆概率治疗加权后,90天净临床获益转换组4.9% vs 继续组5.1%,风险差-0.3个百分点(90%CI -2.7至2.1),达到预设非劣效界值(绝对风险差3.0个百分点)。
- 复发缺血事件和出血结局的绝对差异在预设非劣效界值内。
- 全因死亡和血管死亡未证明非劣效。
证据类型、等级与局限
- 研究类型:多中心注册队列研究,采用模拟目标试验设计,35个卒中中心,9个国家。
- 非劣效比较,预设非劣效界值为90天净临床获益绝对风险差3.0个百分点;采用逆概率治疗加权校正基线混杂。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,对于直接口服抗凝药治疗期间发生突破性缺血性卒中的患者,转换抗凝治疗相比继续同一直接口服抗凝药无额外获益;随机临床试验需要确定改善突破性缺血性卒中后二级预防的策略。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Management after an ischemic stroke occurring despite direct oral anticoagulant (DOAC) therapy for atrial fibrillation (AF) varies widely. Switching anticoagulation is common in clinical practice, although evidence supporting this strategy is limited.
OBJECTIVE: To evaluate whether continuation of treatment with the same DOAC was noninferior to switching oral anticoagulant therapy with respect to 90-day clinical outcomes.
DESIGN, SETTING, AND PARTICIPANTS: This multicenter registry-based cohort study with an emulated target trial design included consecutive adult patients with AF who experienced a breakthrough ischemic stroke while receiving uninterrupted DOAC therapy and resumed anticoagulation therapy thereafter. Patients were enrolled between February 2020 and February 2025, across 35 stroke centers in 9 countries in Europe and North Africa, with a standardized 90-day follow-up. The dataset was locked on September 1, 2025. A noninferiority comparison of switching vs continuation strategies was performed. Baseline confounding was addressed using inverse probability of treatment weighting (IPTW). The primary noninferiority margin was an absolute risk difference of 3.0 percentage points in 90-day net clinical benefit.
EXPOSURE: The intervention group switched to treatment with a different DOAC or vitamin K antagonist; the comparator group continued therapy with the prestroke DOAC.
MAIN OUTCOMES AND MEASURES: The primary outcome was 90-day net clinical benefit, defined as recurrent ischemic stroke and moderate to severe bleeding. Secondary outcomes included recurrent ischemic events, symptomatic intracerebral hemorrhage, moderate to severe extracranial bleeding, all-cause mortality, and vascular death.
RESULTS: Among 1006 patients included in the analysis (median age, 80.4 [IQR, 73.4-85.4] years; 503 female [50.0%] and 503 [50.0%] male), 463 (46.0%) continued the same DOAC therapy and 543 (54.0%) switched therapy. After IPTW adjustment, the 90-day net clinical benefit was 4.9% with switching and 5.1% with continuation, corresponding to a risk difference of -0.3 percentage points (90% CI, -2.7 to 2.1 percentage points), meeting the prespecified noninferiority criterion. For recurrent ischemic events and bleeding outcomes, the absolute differences were within the predefined noninferiority margins. Noninferiority was not demonstrated for all-cause or vascular mortality.
CONCLUSIONS AND RELEVANCE: In patients with breakthrough ischemic stroke during DOAC therapy, switching anticoagulation treatment was not associated with clinically meaningful short-term benefit compared with continuation. These findings suggest that switching does not provide additional benefit compared with continuing treatment with the same DOAC. Randomized clinical trials are needed to identify strategies to improve secondary prevention after a breakthrough ischemic stroke.
参考来源
- D'Anna L, Gabriele F, Ornello R, et al. Continuation vs Switching Direct Oral Anticoagulant Therapy After Breakthrough Stroke. JAMA Netw Open. 2026. PMID: 42048077. doi:10.1001/jamanetworkopen.2026.9584
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。